Systolic blood pressure · People who may be at risk for primary hypertension
2 findings from 1 review
Diastolic blood pressure · People who may be at risk for primary hypertension
1 finding from 1 review
Systolic blood pressure. Dose less than 1000 mg a day (range of · People who may be at risk for primary hypertension
1 finding from 1 review
Systolic blood pressure. Dose between 1000 mg a day and less than 1500 mg a day · People who may be at risk for primary hypertension
1 finding from 1 review
Systolic blood pressure. Dose 1500 mg a day or more (range of · People who may be at risk for primary hypertension
1 finding from 1 review
Systolic blood pressure. 35 years or older (range of · People who may be at risk for primary hypertension
1 finding from 1 review
Secondary outcome: all adverse events · People who may be at risk for primary hypertension
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Variation in the decrease in 24‐hour ambulatory hourly SBP (at 3 to 12 weeks) · adults with primary hypertension
1 finding from 1 review
Variation in the decrease in 24‐hour ambulatory hourly DBP (at 3 to 12 weeks) · adults with primary hypertension
1 finding from 1 review
Total mortality · adults with primary hypertension
First‐line calcium channel blocker showed no clear difference in total mortality compared with placebo (low certainty).
1 finding from 1 review
Stroke · adults with primary hypertension
First‐line calcium channel blocker may leads to lower total stroke compared with placebo (low certainty).
1 finding from 1 review
Total coronary heart disease · adults with primary hypertension
First‐line calcium channel blocker showed no clear difference in total coronary heart disease (CHD) compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular events · adults with primary hypertension
First‐line calcium channel blocker may leads to lower total cardiovascular events compared with placebo (low certainty).
1 finding from 1 review
Calcium channel blocker (any dose) Mean duration of 3 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Cardiovascular events · patients with hypertension
First‐line thiazides probably leads to lower total cardiovascular events Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).
1 finding from 1 review
Stroke · patients with hypertension
First‐line thiazides showed no clear difference in total stroke Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).
1 finding from 1 review
Total CHD Duration: 1 to 5 years · patients with hypertension
First‐line thiazides showed no clear difference in total CHD Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).
1 finding from 1 review
Congestive heart failure · patients with hypertension
First‐line thiazides probably leads to lower total congestive heart failure Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).
1 finding from 1 review
Adverse effects (side effects; treatment withdrawals) · patients with hypertension
First‐line thiazides may leads to lower withdrawals due to adverse effects Duration: 1 to 5 years compared with first‐line calcium channel blockers (low certainty).
1 finding from 1 review
Total mortality Duration: 1 to 5 years · patients with hypertension
First‐line thiazides showed no clear difference in total mortality Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).
1 finding from 1 review